丁苯唑酸 | 50270-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 丁苯唑酸
• 英文名称: 1-Isobutyl-3,4-diphenyl-5-pyrazolessigsaeure
• 英文别名: (2-isobutyl-4,5-diphenyl-2H-pyrazol-3-yl)-acetic acid；1-(2-methylpropyl)-3,4-diphenyl-5-pyrazolylacetic acid；bufezolac；2-[2-(2-methylpropyl)-4,5-diphenylpyrazol-3-yl]acetic acid
• CAS: 50270-32-1
• 化学式: C₂₁H₂₂N₂O₂
• 分子量: 334.418
• InChiKey: JBJASTVVFKIZBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

文献信息

• Novel pharmaceutical compounds
  申请人：Grimm Erich L.

  公开号：US20080188521A1

  公开（公告）日：2008-08-07

  The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  这种瞬间发明提供了化合物I的公式，这些化合物是白三烯生物合成抑制剂。 公式I的化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。
• Process for making substituted pyrazoles
  申请人：——

  公开号：US20030144302A1

  公开（公告）日：2003-07-31

  This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): 1 wherein R 3A , R 3B , R 3C , Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are as defined in the specification.

  这项发明通常涉及制备取代吡唑，取代吡唑的互变异构体，以及取代吡唑和互变异构体的盐的过程。这些取代吡唑在结构上对应于式（I）： 1 其中R 3A ，R 3B ，R 3C ，Y 1 ，Y 2 ，Y 3 ，Y 4 和Y 5 如规范中所定义。
• [EN] 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS<br/>[FR] DERIVES DE 7- (1,3-THIAZOL-2-YL)THIO !COUMARINE ET UTILISATION DE CEUX-CI EN TANT QU'INHIBITEURS DE LA BIOSYNTHESE DES LEUCOTRIENES
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004108720A1

  公开（公告）日：2004-12-16

  The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.

  这种瞬时发明提供了化合物的公式(I)，这些化合物是白三烯生物合成抑制剂。公式(I)的化合物可用作抗哮喘、抗过敏、抗炎、细胞保护和抗动脉粥样硬化药物。
• [EN] 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DES RÉCEPTEURS 5-OXO-ETE
  申请人：UNIV MCGILL

  公开号：WO2010127452A1

  公开（公告）日：2010-11-11

  The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.

  本发明涉及一种新型的药用化合物，它们是5-oxo-ETE受体的拮抗剂，如OXE受体。这些化合物可用作治疗和/或预防组织嗜麻细胞增多等疾病的药物，如包括呼吸道疾病在内的炎症性疾病。该发明还涉及制药组合物，以及将这些化合物和组合物用作药物、以及治疗方法。
• [EN] PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS<br/>[FR] DERIVES DE PYRAZOLS UTILISES COMME INHIBITEURS DE LA P38 KINASE
  申请人：PHARMACIA CORP

  公开号：WO2003104223A1

  公开（公告）日：2003-12-18

  This invention is directed generally to pyrazoles that, inter alia, inhibit p38 kinase, TNF, and/or cyclooxygenase-2 activity. Such pyrazoles include compounds generally corresponding in structure to the following formula (I), wherein L1, L2,Xl, X2, X3, X4, X5, X6, Rl, R3A, R3b,R3C, R4, and R5 are as defined in this specification. The pyrazoles further include tautomers of such compounds, as well as salts of such compounds and tautomers. This invention also is directed to compositions of such pyrazoles, intermediates for the syntheses of such pyrazoles, methods for making such pyrazoles, and methods for treating (including preventing) conditions (particularly pathological conditions) associated with p38 kinase, TNF, and/or cyclooxygenase-2 activity.

  该发明通常涉及对吡唑酮的研究，其可以抑制p38激酶、TNF和/或环氧合酶-2的活性。这些吡唑酮包括通常对应于以下结构式(I)的化合物，其中L1、L2、X1、X2、X3、X4、X5、X6、R1、R3A、R3b、R3C、R4和R5的定义如本说明书所述。这些吡唑酮还包括这些化合物的互变异构体，以及这些化合物和互变异构体的盐。该发明还涉及这些吡唑酮的组合物，合成这些吡唑酮的中间体，制备这些吡唑酮的方法，以及治疗（包括预防）与p38激酶、TNF和/或环氧合酶-2活性相关的病症（特别是病理病症）的方法。